Adcendo Aps
Clinical trials sponsored by Adcendo Aps, explained in plain language.
-
New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New targeted drug enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for rare sarcoma: targeted drug ADCE-D01 enters human trials
Disease control Recruiting nowThis study tests a new drug called ADCE-D01 in people with soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is designed to find and attack cancer cells while leaving healthy cells alone. The trial will check safety, the right dose, and whether it shri…
Phase: PHASE1, PHASE2 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC